Objective. Although 5-year survival for early-stage ovarian cancer is favorable, prognosis at recurrence is poor, necessitating appropriate initial management. We examined the patterns of care and the impact of the duration of chemotherapy on survival for women with early-stage ovarian cancer.
Introduction
Women with early-stage ovarian cancer have a favorable prognosis with five-year survival rates greater than 90% in some subgroups [1] . Standard therapy for early-stage ovarian cancer consists of oophorectomy with surgical staging; prior reports have suggested that approximately 30% of patients with apparent ovary-confined disease have occult nodal, pelvic or abdominal metastases [2] [3] [4] . Low socioeconomic status, advanced age, and minority race/ethnicity are associated with failure to receive recommended comprehensive surgical staging [5] .
Recommended adjuvant therapy for early-stage ovarian cancer depends on tumor sub-stage and grade. Two randomized controlled trials by the Gynecologic Oncology Group (GOG) demonstrated that adjuvant chemotherapy did not provide a survival benefit in patients with lowrisk tumors (stages IA-IB, grades 1-2) [6] . In contrast, patients with high-risk (stages IA-IB grade 3, stage IC, stage II), early-stage ovarian cancer appear to benefit from adjuvant chemotherapy [1, [7] [8] [9] [10] . The benefit of chemotherapy for subsets of patients with early-stage ovarian cancer has subsequently been confirmed in several trials [3, 10, 11] .
Although there is general consensus about the use of adjuvant chemotherapy in high-risk early-stage patients, there is a debate about the optimal duration of chemotherapy. A randomized GOG trial comparing three versus six cycles of platinum and taxane-based chemotherapy showed no survival benefit for extended chemotherapy although this strategy was accompanied by increased toxicity [7] . While the trial concluded that the optimal treatment for these patients is three cycles of chemotherapy, methodologic concerns have led to continued debate about the optimal duration of chemotherapy [1, 9] . While the risk of recurrence for stage I patients is lower, when patients do recur, treatment is palliative [1] . Given these findings, appropriate initial management of early-stage ovarian cancer is paramount.
Given the controversy surrounding the management of early-stage ovarian cancer, we performed a population-based analysis to examine the quality of care and outcomes for women with early-stage ovarian cancer. Specifically, we explored the adherence to guideline-based recommendations for the administration of adjuvant chemotherapy and analyzed the influence of the duration of chemotherapy on survival for early-stage, high-risk patients.
Methods

Data source
The Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database was used for analysis [12] [13] [14] . SEER is a populationbased cancer registry maintained by the National Cancer Institute that provides data on tumor histology, location, stage, treatment, and survival, as well as demographic and selected census tract-level information. The Medicare database includes information on patients with Medicare part A (inpatient) and part B (outpatient) including billed claims, and diagnoses. These two files are linked and provide data on initial services and all follow-up care. Exemption from the Columbia University Institutional Review Board was obtained.
Patient selection
Women aged ≥65 years with stage I epithelial ovarian cancer diagnosed as their first or only cancer between January 1, 1992 and December 31, 2009 were analyzed. Only women who underwent primary cancer-directed surgery including oophorectomy were included [13] . Women who did not have full coverage of both Medicare parts A and B or were enrolled in a non-Medicare health maintenance organization from 12 months prior through 6 months after cancer diagnosis were excluded because the billing claims for these patients were not submitted to Medicare for reimbursement completely [15] . Similarly, women who received chemotherapy prior to surgery were excluded and only those patients who survived for more than 6 months after cancer-directed surgery were included in the analysis. Patients were risk stratified based on previously published data: low-risk (stage IA or IB, grade 1 or 2, non-clear cell histology), high-risk (stage IA or IB grade 3, any stage clear cell histology, stage IC any grade) and unknown risk (insufficient data on grade available to further classify) [6] .
Patient characteristics
Age at diagnosis was categorized into 5-year intervals and race recorded as white, black, and other. Year of diagnosis was stratified into four time periods : 1992-1996, 1997-2001, 2002-2005, and 2006-2009 . The SEER marital status variable was recorded as married, not married, and unknown. An aggregate socioeconomic status (SES) score was calculated from education, poverty level, and income data from the 2000 census tract data, as previously reported by Du and colleagues [16] . Patients' scores were ranked on a scale of 1-5 by the use of the formula that incorporated education, poverty, and income weighted equally, with 1 being the lowest value. To assess the prevalence of comorbid medical diseases, we used the Klabunde adaptation of the Charlson comorbidity index (i.e., the Klabunde-Charlson index) [17, 18] 
Current Procedural Terminology (CPT) codes, ICD-9-CM diagnostic and procedure codes, and revenue center codes from physician claims files, the hospital outpatient claims files, or the Medicare provider review files. If a patient had at least one claim for chemotherapy within 6 months of surgery, she was coded as having received chemotherapy. A second analysis was performed to determine the influence of the duration of chemotherapy on outcomes for high-risk patients [12, 20] . To exclude patients with recurrent and progressive disease, only highrisk patients who received b 8 months of continuous chemotherapy were included. Patients were stratified based on the duration of chemotherapy as ≤3 months and 4-8 months.
To assess adequacy of surgical staging, we evaluated lymphadenectomy. A patient with any pathologic nodal assessment as defined by SEER was considered to have undergone lymphadenectomy.
Statistical analysis
Frequency distributions between categorical variables were compared using χ 2 tests. The Cochran-Armitage test was used to examine changes in the use of chemotherapy over time. Multivariable logistic regression models were developed to determine predictors for chemotherapy use and duration. Separate models were developed for low and high-risk patient groups. Survival was calculated from the date of diagnosis to the date of death. The effect of chemotherapy on survival was examined using the Kaplan-Meier method and the results were compared with the log-rank test. To examine the association between chemotherapy use and survival while controlling for other clinical and demographic variables, Cox proportional hazards models were developed. Separate analyses were performed for overall and cancerspecific survival. All analyses were conducted with SAS, version 9.4 (SAS Institute, Cary, NC). All statistical tests were two-sided. A P-value of b0.05 was considered statistically significant.
Results
We identified a total of 1394 women with stage I epithelial ovarian cancer. The median follow-up time for the cohort was 73 months. The cohort included 477 patients with low-risk tumors, 754 patients with high-risk early-stage tumors and 163 patients classified as unknown risk. The clinical and demographic characteristics of the low-risk patients are displayed (Table 1) .74) neoplasms were also more likely to receive chemotherapy. The use of chemotherapy decreased with advancing age (OR = 0.31; 95% CI, 0.16-0.60 for ≥80 compared to 65-69 years of age). While race was not associated with the receipt of chemotherapy, patients with a comorbidity score of 1 were less likely to receive chemotherapy than those without comorbidities.
Among women with high-risk tumors, chemotherapy was administered to 71.9% of patients (Table 2) . Among women who received chemotherapy, 54.6% underwent lymphadenectomy, while 36.3% of those who did not receive chemotherapy had a node dissection. Chemotherapy use increased from 62.5% (95% CI, 43.1-81.9%) in 1992 to 77.1% (95% CI 66.5-87.6%) in 2009 (P = 0.17) (Fig. 1 ). For patients with high-risk tumors, advancing stage and higher grade were associated with the receipt of chemotherapy (Table 3 ). In contrast, older women were less likely to receive chemotherapy (P b 0.05 for all).
The use of chemotherapy was not associated with survival for women with low-risk tumors. In a multivariable Cox proportional hazards model, chemotherapy use was not associated with improved cancer-specific (HR = 1.62; 95% CI, 0.74-3.56) or overall (HR = 0.93; 95% CI, 0.65-1.33) survival (Table 4 ). Among high-risk patients, the administration of chemotherapy was associated with improved overall survival (HR = 0.70; 95% CI, 0.53-0.91) but not cancer-specific survival (HR = 0.89; 95% CI, 0.59-1.35). Fig. 2A displays a Kaplan-Meier analysis of overall survival for high-risk patients stratified by the receipt of chemotherapy (log-rank P b 0.001).
When the duration of chemotherapy was analyzed among high-risk patients, we noted that 215 (44.2%) women received ≤ 3 months of treatment while 271 (55.8%) received 4-8 months of chemotherapy. chemotherapy for 4-8 months than women with stage IA tumors (OR = 2.22; 95% CI, 1.37-3.59). In contrast, those who underwent lymphadenectomy (OR = 0.51; 95% CI, 0.34-0.79) were less likely to receive longer duration chemotherapy. Among high-risk women who received chemotherapy and after adjustment for clinical and oncologic characteristics, the duration of chemotherapy had no effect on either cancer-specific (HR = 0.93; 95% CI, 0.61-1.42) or overall (HR = 0.93; 95% CI, 0.67-1.27) survival. Likewise, in a Kaplan-Meier analysis, the duration of chemotherapy had no effect on survival (P = 0.76).
Discussion
Our findings demonstrate widespread variation in practice patterns for elderly women with early-stage ovarian cancer. Fewer than half of the women analyzed underwent lymphadenectomy as part of comprehensive surgically staging. More concerning, 28% of women for whom chemotherapy was indicated did not receive treatment, while nearly a third of patients with low-risk tumors who are unlikely to derive benefit from chemotherapy were treated with chemotherapy. These data add to a growing body of literature that suggests that women with early-stage ovarian cancer often receive treatment that is discordant with evidence-based recommendations [21, 22] . Prior studies have shown that comprehensive surgical staging is commonly omitted for women with ovarian cancer [5, [22] [23] [24] [25] [26] . In a study of 4057 earlystage ovarian cancer patients from the Health Care Cost and Utilization Project, only 53% underwent lymph node sampling [22] . Similar to population-based studies in the United States and Europe, our findings demonstrate a lack of adherence to comprehensive surgical staging guidelines in early-stage ovarian cancer, with the omission of lymphadenectomy occurring in the majority of patients [22, 27, 28] . Our study adds to prior analyses by focusing on presumed early-stage disease, a population in whom surgical staging significantly impacts adjuvant treatment planning and survival. In our cohort, only 46.3% of women underwent lymphadenectomy. While performance of lymphadenectomy had no impact on the receipt of chemotherapy for both low and high-risk patients, high-risk women who underwent lymphadenectomy were less likely to receive chemotherapy for N 3 months. Further, one would expect that approximately 30% of the patients in our series would have been upstaged had they undergone lymphadenectomy [24] .
Women with low-risk tumors are unlikely to derive benefit from chemotherapy [6] . Current recommendations by the National Comprehensive Cancer Center (NCCN) recommend observation for patients with stage IA/IB grade 1 tumors and observation or chemotherapy for grade 2 neoplasms [29] . Consistent with these data, we found no improvement in survival for low-risk patients treated with chemotherapy. We did however note that the use of chemotherapy was not only [3, 10, 11] . We noted similar results among our cohort of elderly women with ovarian cancer. Among patients with high-risk, early-stage ovarian cancer, chemotherapy was associated with improved overall survival. In this population the survival benefit was modest and limited to overall survival. Despite the benefits of chemotherapy in this population of women, we noted that 28% of high-risk patients did not receive adjuvant chemotherapy.
Although there is consensus about the benefit of adjuvant chemotherapy for high-risk patients, the optimal duration of chemotherapy remains controversial. While a clinical trial comparing three versus six cycles of chemotherapy demonstrated no survival benefit with six cycles of therapy, these data were only powered to detect N 30% difference in survival [7] . Post-hoc analysis of the GOG data suggested that some groups of women, particularly those with serous histology, derive benefit from longer duration chemotherapy [30] . Our findings are in line with the GOG's data in that there was no improvement in survival for high-risk, early-stage patients treated with longer duration chemotherapy.
While our report benefits from the inclusion of a large sample size, we recognize a number of important limitations. As with any study using administrative data, we cannot control unmeasured confounding factors that undoubtedly influenced not only the decision to utilize chemotherapy, but also the duration of chemotherapy. Using Medicare billing data, it is difficult to precisely determine the number of cycles of chemotherapy administered. To overcome this limitation, we used the duration of chemotherapy as a surrogate for cycles of treatment as has been previously described [31] . Similarly, over the timespan of the study, the therapeutic agents for ovarian cancer and the way these drugs are delivered have evolved. We used a permissive definition of chemotherapy to include treatment with any cytotoxic agent. A priori we also recognize that a large number of patients did not undergo comprehensive staging and may have had occult disease. While this is a limitation in that the reported stage is based on incomplete pathologic assessment, these data capture a "real world" scenario of how patients are managed surgically and how available pathologic data is used to make decisions regarding adjuvant treatment. For some of the subset analyses, particularly for low-risk patients, our sample size and power were limited to detect small differences in survival. Lastly, our data only includes elderly women and may not be generalizable to younger patients.
Our findings demonstrate that the management of early-stage ovarian cancer in clinical practice is widely divergent from evidence-based guidelines in elderly women. Many factors likely contributed to these deviations from standard of care and further efforts should be directed toward exploring why recommended care is not delivered [32, 33] . Given the poor prognosis of recurrent ovarian cancer, initiatives to optimize the management of women with early stage ovarian cancer are clearly warranted. 
